HBIO - ハ―バ―ド・バイオサイエンス (Harvard Bioscience Inc.) ハ―バ―ド・バイオサイエンス

 HBIOのチャート


 HBIOの企業情報

symbol HBIO
会社名 Harvard Bioscience Inc. (ハ―バ―ド・バイオサイエンス)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Biotechnology: Laboratory Analytical Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 ハーバード・バイオサイエンス(Harvard Bioscience Inc.)は世界中の医薬品・バイオ医薬品会社、大学及び政府研究所の生命科学研究を推進するための専門製品、装置及び科学機器の開発・製造・販売に従事するグローバル企業である。同社は850ページのカタログ(及び各種専門カタログ)、ウェブサイト及びGE Healthcare、Thermo Fisher Scientific Inc.とVWR等の流通業者を通じて、100カ国以上の数千人の研究者に製品を販売する。同社の製品は毒性(ADMET)試験及び分子生物学の2つの応用分野をターゲットにする。平成24年2月1日、同社は完全所有子会社Biochrom Ltd.を通してAHN Biotechnologie GmbHの事業を買収した。平成23年7月、同社はCMA Microdialysis AB.の前臨床事業を買収した。   ハ―バ―ド・バイオサイエンスは、米国の医療機器製造会社。製薬会社、バイオテクノ ロジ―会社、大学、政府の実験室など向けに、医薬品研究開発用器具の設計、製造、販売を行う。同社のプロテオミクス関連器具は、たんぱく質および薬剤候補のテストに用いられるADMET (吸収-分布 -代謝-排泄 -毒性) 解析の精製や分析に用いられる。本社は、マサチュ―セッツ州ホリストン。   Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its customers range from renowned academic institutions and government laboratories, to the world's leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, the company sells through a combination of direct and distribution channels to customers around the world.
本社所在地 84 October Hill Road Holliston MA 01746 USA
代表者氏名 James W. Green ジェームズ・W・グリーン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 508-893-8999
設立年月日 1901年
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数 434人
url www.harvardbioscience.com
nasdaq_url https://www.nasdaq.com/symbol/hbio
adr_tso
EBITDA EBITDA(百万ドル) 4.39900
終値(lastsale) 4.61
時価総額(marketcap) 168631946.78
時価総額 時価総額(百万ドル) 156.92650
売上高 売上高(百万ドル) 110.79400
企業価値(EV) 企業価値(EV)(百万ドル) 212.75150
当期純利益 当期純利益(百万ドル) -4.24500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Harvard Bioscience Inc. revenues increased 57% to $58.3M. Net loss before extraordinary items increased from $1.4M to $7.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 73% to $11.7M (expense) Other expense net increase from $105K to $3.1M (expense).

 HBIOのテクニカル分析


 HBIOのニュース

   Data - Harvard Bioscience Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS  2022/05/07 19:43:10 Business Mag
Harvard Bioscience announced its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.04 earnings per share for the quarter, missing the consensus…
   Harvard Bioscience, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:HBIO)  2022/05/05 07:03:17 Seeking Alpha
The following slide deck was published by Harvard Bioscience, Inc.
   Harvard Bioscience, Inc. (HBIO) CEO James Green on Q1 2022 Results - Earnings Call Transcript  2022/05/04 16:36:09 Seeking Alpha
Harvard Bioscience, Inc. (NASDAQ:NASDAQ:HBIO) Q1 2022 Earnings Conference Call May 4, 2022 08:00 ET Company Participants David Sirois - Director of Corporate Accounting & SEC Reporting…
   Harvard Bioscience Non-GAAP EPS of $0.04 misses by $0.02, revenue of $28.78M beats by $0.05M  2022/05/04 11:08:54 Seeking Alpha
Harvard Bioscience press release (NASDAQ:HBIO): Q1 Non-GAAP EPS of $0.04 misses by $0.02.Revenue of $28.78M (+6.6% Y/Y) beats by $0.05M.
   Harvard Bioscience Announces First Quarter 2022 Financial Results  2022/05/04 11:00:00 GlobeNewswire
HOLLISTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2022.
   Strs Ohio Has $679,000 Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO)  2021/12/23 09:22:41 Dakota Financial News
Strs Ohio cut its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 7.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 97,400 shares of the medical instruments suppliers stock after selling 8,100 shares during the quarter. Strs Ohios holdings in Harvard Bioscience were worth $679,000 at the end of the most recent reporting period. []
   Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Bought by Wells Fargo & Company MN  2021/12/12 09:26:42 Transcript Daily
Wells Fargo & Company MN raised its position in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 71.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 423,186 shares of the medical instruments suppliers stock after acquiring an additional 176,253 shares during the quarter. Wells Fargo & Company MNs holdings in Harvard Bioscience were worth $3,525,000 as []
   Analysts Anticipate Harvard Bioscience, Inc. (NASDAQ:HBIO) Will Announce Quarterly Sales of $32.65 Million  2021/12/10 07:40:47 Dakota Financial News
Analysts predict that Harvard Bioscience, Inc. (NASDAQ:HBIO) will report sales of $32.65 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Harvard Biosciences earnings, with the lowest sales estimate coming in at $32.50 million and the highest estimate coming in at $32.80 million. Harvard Bioscience reported sales of $30.98 million []
   Millennium Management LLC Buys 86,058 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)  2021/12/09 09:26:47 Transcript Daily
Millennium Management LLC lifted its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 144.6% during the second quarter, Holdings Channel.com reports. The firm owned 145,562 shares of the medical instruments suppliers stock after acquiring an additional 86,058 shares during the period. Millennium Management LLCs holdings in Harvard Bioscience were worth $1,213,000 as of its []
   13,509 Shares in Harvard Bioscience, Inc. (NASDAQ:HBIO) Acquired by Prudential Financial Inc.  2021/12/02 10:52:45 Dakota Financial News
Prudential Financial Inc. purchased a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,509 shares of the medical instruments suppliers stock, valued at approximately $113,000. Several other hedge funds and other institutional []
   Harvard Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/16 19:39:15 Seeking Alpha
   Harvard Bioscience EPS misses by $0.10, beats on revenue  2021/08/05 11:16:36 Seeking Alpha
   Harvard Bioscience Announces Second Quarter 2021 Financial Results  2021/08/05 11:00:00 Intrado Digital Media
Strong double digit revenue growth, solid margin performance despite global supply chain disruptions
   Global Perfusion Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Getinge, Medtronic, LivaNova, Terumo Medical, Xenios, Lifeline Scientific, XVIVO Perfusion, Repligen Corporation, Spectrum Laboratories, Merck, Harvard Bioscience, Ala Science  2021/07/24 01:08:10 Jumbo News
The report on Global Perfusion Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition of []
   Harvard Bioscience Schedules Second Quarter 2021 Earnings Conference Call for August 5, 2021 at 8:00 AM ET  2021/07/19 20:45:00 Intrado Digital Media
HOLLISTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2021 before the market opens on August 5, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

 関連キーワード  (先端医療機器_テクノロジ― 米国株 ハ―バ―ド・バイオサイエンス HBIO Harvard Bioscience Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)